- Home
- NVS
NVS
Novartis AG
as 10-09-2025 1:25pm EST
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 248.3B | IPO Year: | 1991 |
| Target Price: | $119.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Sell | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.85 | EPS Growth: | -12.59 |
| 52 Week Low/High: | $96.06 - $133.55 | Next Earning Date: | 10-28-2025 |
| Revenue: | $55,186,000,000 | Revenue Growth: | 12.95% |
| Revenue Growth (this year): | 9.06% | Revenue Growth (next year): | 2.54% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 hours ago
Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains
Zacks
20 hours ago
Top Stock Reports for SAP, Novartis & Philip Morris
Barchart
a day ago
Should You Buy Novartis Stock Before October 28?
Zacks
a day ago
Here's Why Novartis (NVS) is a Strong Value Stock
Zacks
a day ago
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Simply Wall St.
2 days ago
Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?
PR Newswire
2 days ago
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
PR Newswire
2 days ago
Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.